Cargando…

Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study

Cancer patients are at risk of suffering from cardiovascular diseases (CVD). Nevertheless, the impact of cardiovascular comorbidity on all-cause mortality (ACM) in large clinical cohorts is not well investigated. In this retrospective cohort study, we collected data from 40,329 patients who were sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Finke, Daniel, Heckmann, Markus B., Wilhelm, Susanna, Entenmann, Lukas, Hund, Hauke, Bougatf, Nina, Katus, Hugo A., Frey, Norbert, Lehmann, Lorenz H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898338/
https://www.ncbi.nlm.nih.gov/pubmed/35312818
http://dx.doi.org/10.1007/s00392-022-02001-6
_version_ 1784882405654396928
author Finke, Daniel
Heckmann, Markus B.
Wilhelm, Susanna
Entenmann, Lukas
Hund, Hauke
Bougatf, Nina
Katus, Hugo A.
Frey, Norbert
Lehmann, Lorenz H.
author_facet Finke, Daniel
Heckmann, Markus B.
Wilhelm, Susanna
Entenmann, Lukas
Hund, Hauke
Bougatf, Nina
Katus, Hugo A.
Frey, Norbert
Lehmann, Lorenz H.
author_sort Finke, Daniel
collection PubMed
description Cancer patients are at risk of suffering from cardiovascular diseases (CVD). Nevertheless, the impact of cardiovascular comorbidity on all-cause mortality (ACM) in large clinical cohorts is not well investigated. In this retrospective cohort study, we collected data from 40,329 patients who were subjected to cardiac catherization from 01/2006 to 12/2017 at University Hospital Heidelberg. The study population included 3666 patients with a diagnosis of cancer prior to catherization and 3666 propensity-score matched non-cancer patients according to age, gender, diabetes and hypertension. 5-year ACM in cancer patients was higher with a reduced left ventricular function (LVEF < 50%; 68.0% vs 50.9%) or cardiac biomarker elevation (high-sensitivity cardiac troponin T (hs-cTnT; 64.6% vs 44.6%) and N-terminal brain natriuretic peptide (NT-proBNP; 62.9% vs 41.4%) compared to cancer patients without cardiac risk. Compared to non-cancer patients, NT-proBNP was found to be significantly higher (median NT-proBNP cancer: 881 ng/L, IQR [254; 3983 ng/L] vs non-cancer: 668 ng/L, IQR [179; 2704 ng/L]; p < 0.001, Wilcoxon-rank sum test) and turned out to predict ACM more accurately than hs-cTnT (NT-proBNP: AUC: 0.74; hs-cTnT: AUC: 0.63; p < 0.001, DeLong’s test) in cancer patients. Risk factors for atherosclerosis, such as diabetes and age (> 65 years) were significant predictors for increased ACM in cancer patients in a multivariate analysis (OR diabetes: 1.96 (1.39–2.75); p < 0.001; OR age > 65 years: 2.95 (1.68–5.4); p < 0.001, logistic regression). Our data support the notion, that overall outcome in cancer patients who underwent cardiac catherization depends on cardiovascular comorbidities. Therefore, particularly cancer patients may benefit from standardized cardiac care. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-022-02001-6.
format Online
Article
Text
id pubmed-9898338
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-98983382023-02-05 Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study Finke, Daniel Heckmann, Markus B. Wilhelm, Susanna Entenmann, Lukas Hund, Hauke Bougatf, Nina Katus, Hugo A. Frey, Norbert Lehmann, Lorenz H. Clin Res Cardiol Original Paper Cancer patients are at risk of suffering from cardiovascular diseases (CVD). Nevertheless, the impact of cardiovascular comorbidity on all-cause mortality (ACM) in large clinical cohorts is not well investigated. In this retrospective cohort study, we collected data from 40,329 patients who were subjected to cardiac catherization from 01/2006 to 12/2017 at University Hospital Heidelberg. The study population included 3666 patients with a diagnosis of cancer prior to catherization and 3666 propensity-score matched non-cancer patients according to age, gender, diabetes and hypertension. 5-year ACM in cancer patients was higher with a reduced left ventricular function (LVEF < 50%; 68.0% vs 50.9%) or cardiac biomarker elevation (high-sensitivity cardiac troponin T (hs-cTnT; 64.6% vs 44.6%) and N-terminal brain natriuretic peptide (NT-proBNP; 62.9% vs 41.4%) compared to cancer patients without cardiac risk. Compared to non-cancer patients, NT-proBNP was found to be significantly higher (median NT-proBNP cancer: 881 ng/L, IQR [254; 3983 ng/L] vs non-cancer: 668 ng/L, IQR [179; 2704 ng/L]; p < 0.001, Wilcoxon-rank sum test) and turned out to predict ACM more accurately than hs-cTnT (NT-proBNP: AUC: 0.74; hs-cTnT: AUC: 0.63; p < 0.001, DeLong’s test) in cancer patients. Risk factors for atherosclerosis, such as diabetes and age (> 65 years) were significant predictors for increased ACM in cancer patients in a multivariate analysis (OR diabetes: 1.96 (1.39–2.75); p < 0.001; OR age > 65 years: 2.95 (1.68–5.4); p < 0.001, logistic regression). Our data support the notion, that overall outcome in cancer patients who underwent cardiac catherization depends on cardiovascular comorbidities. Therefore, particularly cancer patients may benefit from standardized cardiac care. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-022-02001-6. Springer Berlin Heidelberg 2022-03-21 2023 /pmc/articles/PMC9898338/ /pubmed/35312818 http://dx.doi.org/10.1007/s00392-022-02001-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Finke, Daniel
Heckmann, Markus B.
Wilhelm, Susanna
Entenmann, Lukas
Hund, Hauke
Bougatf, Nina
Katus, Hugo A.
Frey, Norbert
Lehmann, Lorenz H.
Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study
title Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study
title_full Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study
title_fullStr Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study
title_full_unstemmed Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study
title_short Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study
title_sort coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898338/
https://www.ncbi.nlm.nih.gov/pubmed/35312818
http://dx.doi.org/10.1007/s00392-022-02001-6
work_keys_str_mv AT finkedaniel coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy
AT heckmannmarkusb coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy
AT wilhelmsusanna coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy
AT entenmannlukas coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy
AT hundhauke coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy
AT bougatfnina coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy
AT katushugoa coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy
AT freynorbert coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy
AT lehmannlorenzh coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy